studies have demonstrated that esophageal adenocarcinoma cells and xenograft tumors can be resistant to trastuzumab and pertuzumab by activating TGF-β signaling, which induces epithelial-mesenchymal transition. The gene discussed is TGFB1; the disease is esophageal adenocarcinoma.